Johnson & Johnson Gross Profit 2011-2026 | JNJ

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Johnson & Johnson

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
63.9 B	61.4 B	58.6 B	13.8 B	54.2 B	-	54.6 B	54.6 B	50.2 B	48.6 B	-	51.6 B	49.7 B	44.8 B	42.8 B

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
63.9 B	13.8 B	49.9 B

Quarterly Gross Profit Johnson & Johnson

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
16.7 B	16.1 B	14.5 B	15.5 B	15.6 B	14.9 B	14.7 B	15.1 B	14.2 B	-	13.8 B	16.1 B	15.8 B	-	16.1 B	15.7 B	15.3 B	-	14.1 B	11.8 B	13.6 B	13.6 B	13.9 B	13.6 B	13.4 B	13.4 B	13.8 B	13.9 B	13.4 B	12.9 B	12.7 B	13 B	12.4 B	12.1 B	12.3 B	13.1 B	12.2 B	-	11.9 B	12.4 B	12.1 B	12.4 B	13.1 B	13.5 B	12.7 B	12.4 B	12.2 B	12.4 B	12 B	11.6 B	11.5 B	11.3 B	11.2 B	10.6 B	10.9 B	11.4 B	11.4 B

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
16.7 B	10.6 B	13.3 B

Gross Profit of other stocks in the Biotechnology industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	180 M	-	2.43 %	$ 254 M	Germany
Acer Therapeutics ACER	1.27 M	-	2.71 %	$ 14 M	USA
Cabaletta Bio CABA	0.006	$ 3.34	0.45 %	$ 3.9 M	USA
Alexion Pharmaceuticals, Inc. ALXN	5.52 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	102 K	-	-10.17 %	$ 12.2 K	USA
Codexis CDXS	52.8 M	$ 1.02	1.49 %	$ 74.9 M	USA
Cerus Corporation CERS	60.4 M	$ 2.6	1.37 %	$ 480 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-428 K	-	-18.52 %	$ 27.3 M	Britain
Cellectis S.A. CLLS	37.7 M	$ 3.87	-0.39 %	$ 116 M	France
Acorda Therapeutics ACOR	119 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-32.3 K	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	2.32 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	774 M	-	-	-	Russia
AIkido Pharma AIKI	10 K	-	1.93 %	$ 17.4 M	USA
Collegium Pharmaceutical COLL	128 M	$ 41.75	0.19 %	$ 1.32 B	USA
Albireo Pharma ALBO	39.2 M	-	-0.23 %	$ 916 M	USA
Corcept Therapeutics Incorporated CORT	301 M	$ 36.14	1.23 %	$ 3.75 B	USA
Amarin Corporation plc AMRN	166 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
Catalyst Pharmaceuticals CPRX	87.5 M	$ 23.77	2.99 %	$ 2.91 B	USA
Corbus Pharmaceuticals Holdings CRBP	3.94 M	$ 8.41	-1.87 %	$ 36.4 M	USA
Cardiff Oncology CRDF	245 K	$ 1.94	0.01 %	$ 130 M	USA
Curis CRIS	9.5 M	$ 1.1	-3.51 %	$ 6.94 M	USA
Aeterna Zentaris AEZS	4.73 M	-	5.93 %	$ 314 M	Canada
CorMedix CRMD	61.7 K	$ 7.16	0.42 %	$ 364 M	USA
Ampio Pharmaceuticals AMPE	-523 K	-	-11.43 %	$ 502 K	USA
Champions Oncology CSBR	12.8 M	$ 6.14	3.89 %	$ 83.9 M	USA
Aravive ARAV	5.68 K	-	-13.39 %	$ 1.45 M	USA
Aptinyx APTX	1.56 K	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	1 K	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	8.18 K	$ 4.21	-2.32 %	$ 299 M	USA
CEL-SCI Corporation CVM	255 K	$ 3.88	-8.92 %	$ 247 M	USA